Laboratory staffing and supply shortages limited patient access to cancer screening tests, and the pandemic decreased the development and validation of new tests.
The lab will use its phlebotomy network to help Grail with specimen collection for its Galleri multi-cancer early detection blood test, slated to launch this year.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
G+FLAS said it provides CRISPR-related research services, tools, and reagents and applies CRISPR technology to develop drugs and produce genome-edited plants.
The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.
The tumor microenvironment (TME) is comprised of an array of cell types, including immune and inflammatory cells, adipose cells, neuroendocrine cells, and cancer-associated fibroblasts. Additionally, blood and lymphatic vascular networks and extracellular matrix components create a diverse and multifaceted situation. Understanding how all of these elements interact requires the ability to distinguish individual cell types--something that is difficult to do using bulk cell approaches. Single cell gene expression analyses offer a high-resolution understanding of the TME.
Carrier screening to detect the presence of heritable genetic defects has been an important element of reproductive health strategies for over 50 years. Until recently, however, the practice has been restricted to a limited number of single-gene tests offered mainly to higher-risk individuals or populations based on race, ethnicity, or ancestry. But the landscape of carrier screening and its role in reproductive health are changing fast.
